Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Processa Pharmaceuticals (PCSA)
NASDAQ:PCSA
RESEARCH TOOLSreports
Holding PCSA?
Track your performance easily
PCSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.05 - $17.42
Previous Close$1.1
Volume15.25K
Average Volume (3M)76.33K
Market Cap
$3.63M
Enterprise Value$725.98K
Total Cash (Recent Filing)$2.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 27, 2025EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.02
Shares Outstanding3,266,944
10 Day Avg. Volume24,766
30 Day Avg. Volume76,330
Standard Deviation0.31
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.98
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.12
Forecast
1Y Price Target
$6.00Price Target Upside435.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Processa Pharmaceuticals News
PremiumCompany Announcements
Processa Pharmaceuticals Reports Q3 2024 Financial Results
PremiumMarket News
3 Penny Stocks to Watch Now, 8/1/24Bulls Say, Bears Say
Bulls Say
Clinical TrialsProcessa Pharmaceuticals announced that the first patient has been dosed in a Phase 2 trial evaluating NGC-Cap for the treatment of advanced or metastatic breast cancer.
Preclinical DataProcessa Pharmaceuticals reported positive data from preclinical studies that support the potential for NGC-Iri to demonstrate improved clinical efficacy and safety compared to commonly used FDA-approved chemotherapeutic agents.
Regulatory ApprovalThe FDA has cleared the Investigational New Drug (IND) application for Processa's next-generation capecitabine (NGC-Cap), the company's lead product candidate.
Bears Say
Clinical TrialsThere are risks of clinical setbacks with Processa's oncology portfolio, particularly with NGC-Cap, which could hinder development progress.
Market CompetitionGreater-than-anticipated levels of competition, including the availability of generic options, could result in lower-than-projected pricing and market penetration for the company's products.
Regulatory ApprovalsFailure to secure regulatory approvals for Processa's oncology assets in the United States poses a significant risk to the company's future prospects.
---
Ownership Overview
11.65% Insiders
1.26% Mutual Funds
<0.01% Other Institutional Investors
86.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PCSA FAQ
What was Processa Pharmaceuticals’s price range in the past 12 months?
Processa Pharmaceuticals lowest stock price was $1.05 and its highest was $17.42 in the past 12 months.
What is Processa Pharmaceuticals’s market cap?
Currently, no data Available
When is Processa Pharmaceuticals’s upcoming earnings report date?
Processa Pharmaceuticals’s upcoming earnings report date is Mar 27, 2025 which is in 137 days.
How were Processa Pharmaceuticals’s earnings last quarter?
Processa Pharmaceuticals released its earnings results on Oct 30, 2024. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$1 by -$0.03.
Is Processa Pharmaceuticals overvalued?
According to Wall Street analysts Processa Pharmaceuticals’s price is currently Undervalued.
Does Processa Pharmaceuticals pay dividends?
Processa Pharmaceuticals does not currently pay dividends.
What is Processa Pharmaceuticals’s EPS estimate?
Processa Pharmaceuticals’s EPS estimate is -$0.76.
How many shares outstanding does Processa Pharmaceuticals have?
Processa Pharmaceuticals has 3,266,944 shares outstanding.
What happened to Processa Pharmaceuticals’s price movement after its last earnings report?
Processa Pharmaceuticals reported an EPS of -$1.03 in its last earnings report, missing expectations of -$1. Following the earnings report the stock price went down -12.782%.
Which hedge fund is a major shareholder of Processa Pharmaceuticals?
Currently, no hedge funds are holding shares in PCSA
---
Processa Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (435.71% Upside)
$6.00 (435.71% Upside)
Blogger Sentiment
Bullish
PCSA Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.19%
12-Months-Change
Fundamentals
Return on Equity
-211.71%
Trailing 12-Months
Asset Growth
-38.86%
Trailing 12-Months
Company Description
Processa Pharmaceuticals
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. It focuses on its product, PCS-499, which is an oral tablet that is a deuterated analog of an active metabolite of an already approved drug. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on October 2, 2017 and is headquartered in Hanover, MD.
---
PCSA Earnings Call
Q4 2023
0:00 / 0:00
---
PCSA Stock 12 Month Forecast
Average Price Target
$6.00
▲(435.71% Upside)
Technical Analysis
Best Analysts Covering PCSA
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-37.30%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -37.30% per trade.
---